Form 4: Inhibrx Biosciences CFO Kelly Deck Acquires 15,000 Stock Options

Kelly Deck, CFO of Inhibrx Biosciences, acquired 15,000 stock options on April 1, 2025, according to a Form 4 filing with the SEC.

Summary

• On April 1, 2025, Kelly Deck, the Chief Financial Officer of Inhibrx Biosciences, Inc. (INBX), acquired 15,000 stock options.
• The exercise price of these options is $14.05 per share.
• The options vest over a period of four years, with 25% becoming exercisable on April 1, 2026, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continuous service to the company.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a standard transaction of stock options being granted to a company executive. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Stakeholder Impact

• The acquisition of stock options by the CFO could potentially align management's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Key Dates

Keywords

stock options, Form 4, Inhibrx Biosciences, Kelly Deck, CFO, INBX, acquisition, vesting